1 in 1,000 Privately Insured 17-Year-Olds Were Taking Cross-Sex Hormones Prior to State Bans
The authors of a new study analyzing 2018 to 2022 insurance claims data characterized such prescriptions as rare and said this rarity undermined arguments for bans of these interventions.
The video above is
